Vericel (VCEL) Rating Increased to Strong-Buy at BidaskClub

BidaskClub upgraded shares of Vericel (NASDAQ:VCEL) from a buy rating to a strong-buy rating in a research report released on Friday.

VCEL has been the subject of several other research reports. BTIG Research reiterated a buy rating and set a $13.00 price objective (up previously from $8.00) on shares of Vericel in a research report on Monday, March 5th. ValuEngine upgraded shares of Vericel from a sell rating to a hold rating in a research report on Friday, February 2nd. Piper Jaffray reissued an overweight rating and issued a $9.00 target price on shares of Vericel in a research note on Tuesday, January 2nd. Leerink Swann began coverage on shares of Vericel in a research note on Wednesday, April 4th. They issued an outperform rating and a $15.00 target price on the stock. Finally, Ladenburg Thalmann downgraded shares of Vericel from a buy rating to a neutral rating in a research note on Tuesday, March 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $14.25.

How to Become a New Pot Stock Millionaire

VCEL stock opened at $11.55 on Friday. Vericel has a 52 week low of $2.35 and a 52 week high of $13.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57. The firm has a market cap of $434.54, a price-to-earnings ratio of -23.10 and a beta of 3.18.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Monday, March 5th. The biotechnology company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. The business had revenue of $23.35 million during the quarter. research analysts anticipate that Vericel will post -0.24 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Vericel in the third quarter valued at $328,000. First Washington CORP raised its stake in shares of Vericel by 20.1% in the fourth quarter. First Washington CORP now owns 809,027 shares of the biotechnology company’s stock valued at $4,409,000 after acquiring an additional 135,600 shares during the period. Broadfin Capital LLC purchased a new stake in shares of Vericel in the fourth quarter valued at $472,000. RTW Investments LP purchased a new stake in shares of Vericel in the fourth quarter valued at $7,111,000. Finally, Bank of Montreal Can purchased a new stake in shares of Vericel in the fourth quarter valued at $140,000. 36.91% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Vericel (VCEL) Rating Increased to Strong-Buy at BidaskClub” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2018/04/16/vericel-vcel-rating-increased-to-strong-buy-at-bidaskclub.html.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply